Ellis Kathryn A, Szoeke Cassandra, Bush Ashley I, Darby David, Graham Petra L, Lautenschlager Nicola T, Macaulay S Lance, Martins Ralph N, Maruff Paul, Masters Colin L, McBride Simon J, Pike Kerryn E, Rainey-Smith Stephanie R, Rembach Alan, Robertson Joanne, Rowe Christopher C, Savage Greg, Villemagne Victor L, Woodward Michael, Wilson William, Zhang Ping, Ames David
Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne; St. Vincent's Aged Psychiatry Service, St George's Hospital, Kew, Victoria, Australia.
National Ageing Research Institute (NARI), Parkville, Victoria, Australia.
Int Psychogeriatr. 2014 Apr;26(4):543-54. doi: 10.1017/S1041610213001956. Epub 2013 Nov 20.
The Australian Imaging, Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing is a prospective study of 1,112 individuals (211 with Alzheimer's disease (AD), 133 with mild cognitive impairment (MCI), and 768 healthy controls (HCs)). Here we report diagnostic and cognitive findings at the first (18-month) follow-up of the cohort. The first aim was to compute rates of transition from HC to MCI, and MCI to AD. The second aim was to characterize the cognitive profiles of individuals who transitioned to a more severe disease stage compared with those who did not.
Eighteen months after baseline, participants underwent comprehensive cognitive testing and diagnostic review, provided an 80 ml blood sample, and completed health and lifestyle questionnaires. A subgroup also underwent amyloid PET and MRI neuroimaging.
The diagnostic status of 89.9% of the cohorts was determined (972 were reassessed, 28 had died, and 112 did not return for reassessment). The 18-month cohort comprised 692 HCs, 82 MCI cases, 197 AD patients, and one Parkinson's disease dementia case. The transition rate from HC to MCI was 2.5%, and cognitive decline in HCs who transitioned to MCI was greatest in memory and naming domains compared to HCs who remained stable. The transition rate from MCI to AD was 30.5%.
There was a high retention rate after 18 months. Rates of transition from healthy aging to MCI, and MCI to AD, were consistent with established estimates. Follow-up of this cohort over longer periods will elucidate robust predictors of future cognitive decline.
澳大利亚影像、生物标志物与生活方式（AIBL）衰老旗舰研究是一项针对1112名个体的前瞻性研究（211例阿尔茨海默病（AD）患者、133例轻度认知障碍（MCI）患者和768名健康对照（HC））。在此，我们报告该队列首次（18个月）随访时的诊断和认知结果。第一个目标是计算从HC转变为MCI以及从MCI转变为AD的发生率。第二个目标是描述与未转变至更严重疾病阶段的个体相比，转变至更严重疾病阶段的个体的认知特征。
在基线后的18个月，参与者接受了全面的认知测试和诊断复查，提供了80毫升血液样本，并完成了健康和生活方式问卷。一个亚组还接受了淀粉样蛋白PET和MRI神经影像学检查。
确定了89.9%队列的诊断状态（972人接受了重新评估，28人死亡，112人未返回接受重新评估）。18个月的队列包括692名HC、82例MCI病例、197例AD患者和1例帕金森病痴呆病例。从HC转变为MCI的发生率为2.5%，与保持稳定的HC相比，转变为MCI的HC在记忆和命名领域的认知衰退最为明显。从MCI转变为AD的发生率为30.5%。
18个月后的保留率较高。从健康衰老转变为MCI以及从MCI转变为AD的发生率与既定估计一致。对该队列进行更长时间的随访将阐明未来认知衰退的有力预测因素。
